CD274 and cancer: These include immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1, therapeutic cancer vaccines like Sipuleucel-T, bi-specific T cell engagers (BiTEs), and chimeric antigen receptor T-cells (CAR-T) (19, 20).